Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer

NCT04025372 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT04025372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04025372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2020
Completion date
March 1, 2028
Enrollment
234 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer